- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05468047
Ketamine Therapy Experiential Education Study (KTEES1)
Effects of a Personal Ketamine-assisted Therapy Experience on Clinicians' Therapeutic Competencies Within a Psychedelic-assisted Therapy Training Program
This study investigates the use of low-dose (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection, USP administered intramuscularly to healthy clinicians as part of an experiential learning practice within a psychedelic-assisted therapy (PAT) training program. The primary objective of this study is to test the hypothesis that competencies required for mental healthcare professionals providing PAT are enhanced by undergoing a single ketamine-assisted therapy experience, as part of a PAT training program.
Primary outcomes of this study are self-reported measures of therapeutic efficacy and competency for providing both general and psychedelic-assisted therapy, measured at baseline and four weeks following an academic in-person retreat with optional ketamine administration. Secondary endpoints include measures of personality and magnitude of perceived mystical experiences. Individual changes in scores across time will be calculated, and differences in therapeutic efficacy and competency between clinician trainees who choose to participate in a personal ketamine-assisted therapy session and those who do not will be assessed.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-85 years old
- Are proficient in reading and speaking English
- Competent in decision making capacity
- Enrolled in the IPI Psychedelic Assisted Therapy Training Program
- For those being administered ketamine, able and willing to commit to medication dose, attending all study sessions during the In-Person Experiential Training Weekend, and evaluation instruments
- For those being administered ketamine, willing to refrain from using stimulants, anxiolytics during the day of the study session
- May continue but not change psychiatric medications during the course of the study
- Agree to refrain from using stimulants, anxiolytics during the day of the study sessions
- Agree to refrain from alcohol and marijuana for 24 hours before and the day of study sessions
- Agree to refrain from the use of any psychoactive drug during the course of the study
- Willing to be recorded by video and audio for safety purposes only
- Agree to not operate a car or any other heavy equipment for the rest of the day after the ketamine administration
- If necessary, are willing to be contacted via telephone on a daily basis by the therapist or team after each experiential session
- Able to identify one or two caregiver support persons who can drive participant home, be reached by the team, and provide collateral information as needed
- Willing to inform the investigator within 48 hours if any medical conditions occur or procedures are planned
Exclusion Criteria:
- Unable to provide informed consent
- Anyone currently taking medications contraindicated for ketamine, such as benzodiazepine or lamotrigine
- Anyone deemed at medical screening medically unfit for ketamine exposure including but not limited to:
- prior history of psychotic disorder
- prior history of unstable bipolar disorder
- prior history of personality disorder
- prior history of ketamine use disorder
- active substance use disorder
- untreated migraine headaches
- uncontrolled hypertension
- cardiovascular disease without approval of physician of record
- active or recent suicidal ideation
- pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ketamine administration
These individuals will be provided a personal ketamine-assisted therapy experience as part of an in-person training weekend within a psychedelic-assisted training program.
|
Individuals will be administered a single dose of sub-anesthetic (0.5-0.75 mg/kg; maximum dose of 60 mg regardless of body weight) ketamine hydrochloride injection intramuscularly as part of a ketamine-assisted therapy experience.
|
No Intervention: No ketamine administration
These individuals will undergo the same psychedelic-assisted training program as those who receive the ketamine experience and will attend the same in-person training weekend; however, these individuals have opted out of ketamine administration by choice or due to contraindication and will not participate in the personal experience.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of Psychotherapists Common Core Questionnaire
Time Frame: 5 weeks
|
Scale measuring perceived determinants of professional development as a therapist; this study uses Subscales 8 (21 questions) and 10-1 (1 question) of the DPCCQ.
This multi-dimensional measure of therapist development uses questions based on a Likert scale that range from 0 (worst outcome) to 5 (best outcome), -3 (worst outcome) to 3 (best outcome), and 1 (worst outcome) to 6 (best outcome).
|
5 weeks
|
Counseling Self Estimate Inventory
Time Frame: 5 weeks
|
Scale measuring self-reported measures of general counseling efficacy; Likert scale ranging from 1 (worst outcome) to 6 (best outcome) for each of 37 items.
|
5 weeks
|
Psychedelic-Assisted Therapist Self-Efficacy Scale
Time Frame: 5 weeks
|
Scale designed to assess psychedelic-assisted therapy-related competencies as defined in the IPI PAT Training Program; Likert scale ranging from 1 (worst outcome) to 5 (best outcome) for each of 45 items.
|
5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Big-Five Inventory-2
Time Frame: 5 weeks
|
Self reported personality questionnaire; Likert scale ranging from 1 (worst outcome) to 5 (best outcome) for each of 60 items.
|
5 weeks
|
Mystical Experiences Questionnaire
Time Frame: 3 days
|
Self-reported scale that assesses ketamine-associated mystical experience and its impact on personal and professional life; Likert scale ranging from 1 (worst outcome) to 5 (best outcome) for each of 30 items.
|
3 days
|
Columbia Suicide Severity Rating Scale- "Baseline" and "Since Last Visit" versions
Time Frame: 5 weeks
|
Self-reported assessment of suicidal ideation and behavior; Yes or No questions assess suicidal ideation and behavior, while Likert scales ranging from 0 (best outcome) to 5 (worst outcome), 1 (best outcome) to 5 (best outcome), or 0 (best outcome) to 2 (worst outcome) for 7 items assess severity.
|
5 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographic questionnaire
Time Frame: 1 day
|
Self-reported baseline demographic information about participants that may be associated with outcomes
|
1 day
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
- KTEES1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychedelic Experiences
-
University of Wisconsin, MadisonUsona Institute; Tiny Blue Dot FoundationEnrolling by invitationHealthy | Sleep | Psychedelic ExperiencesUnited States
-
Robin Carhart-Harris, PhD, MARecruitingHealthy Volunteers | Psychedelic Experiences | NeuroimagingUnited States
-
University of Wisconsin, MadisonTiny Blue Dot FoundationNot yet recruitingHealthy | Vagus Nerve Stimulation | Psychedelic ExperiencesUnited States
-
Empower Research IncCompletedDepressive Disorder | Depression | PTSD | Anxiety Disorders | Anxiety | Psychological | Psychedelic Experiences | Psychedelic Drug DependenceCanada
-
University of MinnesotaHeffter Research InstituteRecruitingPsychedelic Experiences | Perception Disturbance | Visual SuppressionUnited States
-
University of Wisconsin, MadisonCompleted
-
Optimi Health CorporationUniversity of CalgaryWithdrawnHealth, Subjective | Anxiety | Sleep Disturbance | Drug Effect | Psychedelic Experiences | Mood Change | Mood Disturbance | Psilocin Toxicity | Psilocybin Toxicity | Psilocybin Causing Adverse Effects in Therapeutic Use
-
The University of Texas Health Science Center,...Merck Sharp & Dohme LLCCompletedPrEP Uptake Perspectives | PrEP Uptake Experiences | PrEP Adherence Perspectives | PrEP Adherence ExperiencesUnited States
-
University of East LondonCompleted
Clinical Trials on Ketamine hydrochloride injection
-
Juvenile Bipolar Research FoundationTerminatedBipolar DisorderUnited States
-
Haihe Biopharma Co., Ltd.Shanghai Institute of Materia Medica, Chinese Academy of SciencesCompletedAdvanced Solid TumorChina
-
Ciusss de L'Est de l'Île de MontréalRecruiting
-
Xianhai MaoChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingHepatocellular Carcinoma | Adjuvant TherapyChina
-
Tianjin Medical University General HospitalRecruitingPostoperative Pain | Postoperative Cognitive DysfunctionChina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruiting
-
Isfahan University of Medical SciencesUnknownProcedural SedationIran, Islamic Republic of
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Case Comprehensive Cancer CenterActive, not recruitingOpioid Consumption | Postoperative Pain ControlUnited States